{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125334","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.945269+00:00","generated_at":"2026-05-30T01:56:45.141035+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atara Q3 net loss narrows to $21.9M; tab-cel PDUFA Jan 15, 2025; CLO departs","bullets":["Net loss $21.9M ($2.93/share) vs $69.8M ($16.40) YoY; revenue rose to $40.2M from $2.1M.","Cash, equivalents & investments $67.2M; net cash used in ops $4.0M vs $51.3M; cash runway into 2027.","Tab-cel BLA on track; PDUFA Jan 15, 2025; no advisory committee; potential $60M milestone from Pierre Fabre.","First patient dosed in ATA3219 NHL study; initial data Q1 2025. Lupus nephritis study start by year-end; data mid-2025.","Chief Legal Officer Amar Murugan departed Nov 8; consulting role at $250/hr; severance and bonuses tied to tab-cel milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125334","json":"https://secwatch.observer/filing/0000950170-24-125334.json","markdown":"https://secwatch.observer/filing/0000950170-24-125334.md","text":"https://secwatch.observer/filing/0000950170-24-125334.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/0000950170-24-125334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:56:45.141035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d74226f1f4","claim":"Amar Murugan departed as Chief Legal Officer at Atara Biotherapeutics, Inc..","evidence_excerpt":"On November 8, 2024, it was agreed that the employment of Amar Murugan, the Company’s Chief Legal Officer, would end effective November 8, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/0000950170-24-125334-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Legal Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}